Bellevue Group Ag Alnylam Pharmaceuticals, Inc. Transaction History

Bellevue Group Ag

$6.38 Billion
Q1 2024

A detailed history of Bellevue Group Ag transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 918,284 shares of ALNY stock, worth $228 Million. This represents 2.15% of its overall portfolio holdings.

Number of Shares

918,284

Previous 885,318 3.72%

Holding current value

$228 Million

Previous $169 Million 19.01%

% of portfolio

2.15%

Previous 2.63%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $4.83 Million - $6.53 Million	32,966 Added 3.72%	918,284 $137 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $1.37 Million - $1.77 Million	-9,027 Reduced 1.01%	885,318 $169 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $905,934 - $1.12 Million	-5,305 Reduced 0.59%	894,345 $158 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $3.03 Million - $3.48 Million	16,400 Added 1.86%	899,650 $171 Million
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $6.93 Million - $8.94 Million	-37,963 Reduced 4.12%	883,250 $177 Million

Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $6.6 Million - $8.58 Million	-35,549 Reduced 3.72%	921,213 $219 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $14.1 Million - $23.5 Million	-101,424 Reduced 9.58%	956,762 $192 Million
Q2 2022 Aug 11, 2022	SELL	$120.42 - $169.29 $20.6 Million - $29 Million	-171,377 Reduced 13.94%	1,058,186 $154 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $13.4 Million - $18.4 Million	-105,577 Reduced 7.91%	1,229,563 $201 Million
Q4 2021 Feb 10, 2022	SELL	$159.56 - $209.29 $11.7 Million - $15.3 Million	-73,278 Reduced 5.2%	1,335,140 $226 Million
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $23.9 Million - $29.2 Million	-140,674 Reduced 9.08%	1,408,418 $266 Million
Q2 2021 Aug 12, 2021	SELL	$128.63 - $176.89 $10 Million - $13.8 Million	-78,022 Reduced 4.8%	1,549,092 $263 Million
Q1 2021 May 12, 2021	BUY	$126.83 - $175.69 $2.99 Million - $4.15 Million	23,614 Added 1.47%	1,627,114 $230 Million
Q4 2020 Feb 16, 2021	BUY	$122.97 - $147.0 $5.37 Million - $6.42 Million	43,695 Added 2.8%	1,603,500 $208 Million
Q3 2020 Nov 16, 2020	SELL	$121.19 - $165.49 $6.09 Million - $8.32 Million	-50,260 Reduced 3.12%	1,559,805 $227 Million
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $17.2 Million - $25.8 Million	-165,199 Reduced 9.31%	1,610,065 $238 Million
Q1 2020 May 14, 2020	SELL	$93.12 - $133.99 $8.34 Million - $12 Million	-89,519 Reduced 4.8%	1,775,264 $193 Million
Q4 2019 Feb 14, 2020	SELL	$74.51 - $124.23 $7.47 Million - $12.5 Million	-100,289 Reduced 5.1%	1,864,783 $215 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $2.67 Million - $3.31 Million	37,678 Added 1.95%	1,965,072 $158 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $109 Million - $154 Million	1,660,089 Added 621.05%	1,927,394 $140 Million
Q1 2019 May 15, 2019	BUY	$72.76 - $93.45 $3.12 Million - $4.01 Million	42,920 Added 19.13%	267,305 $25 Million
Q4 2018 Feb 12, 2019	BUY	$62.67 - $88.33 $281,638 - $396,955	4,494 Added 2.04%	224,385 $16.4 Million
Q3 2018 Nov 13, 2018	BUY	$87.52 - $122.67 $10.2 Million - $14.3 Million	116,391 Added 112.46%	219,891 $19.2 Million
Q2 2018 Aug 07, 2018	BUY	$88.31 - $107.8 $7.22 Million - $8.81 Million	81,750 Added 375.86%	103,500 $10.2 Million
Q1 2018 May 09, 2018	SELL	$115.92 - $148.54 $40,572 - $51,989	-350 Reduced 1.58%	21,750 $2.59 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $6.12 Million - $7.49 Million	-53,493 Reduced 70.76%	22,100 $2.81 Million
Q3 2017 Nov 13, 2017	SELL	$72.53 - $118.27 $3.59 Million - $5.85 Million	-49,436 Reduced 39.54%	75,593 $8.88 Million
Q2 2017 Aug 14, 2017	BUY	N/A	125,029	125,029 $9.97 Million

Others Institutions Holding ALNY

# of Institutions

585

Shares Held

104M

Call Options Held

2.82M

Put Options Held

1.75M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Alnylam Pharmaceuticals, Inc. Transaction History